Status:
COMPLETED
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Ovarian Neoplasms
Eligibility:
FEMALE
18-130 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurabl...
Eligibility Criteria
Inclusion
- Advanced ovarian cancer with positive BRCA1 or BRCA2 status
- Progressive or recurrent disease after platinum-based chemotherapy
- Measurable disease by RECIST
Exclusion
- Previous anthracycline treatment
- Brain metastases
- Less than 28 days since last treatment used to treat the disease
- Considered a poor medical risk due to a serious uncontrolled disorder
Key Trial Info
Start Date :
July 30 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2018
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT00628251
Start Date
July 30 2008
End Date
September 19 2018
Last Update
December 5 2019
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Los Angeles, California, United States, 90048
2
Research Site
San Francisco, California, United States, 94115
3
Research Site
Boca Raton, Florida, United States, 33428
4
Research Site
Boston, Massachusetts, United States, 02115